Publication: 3076

Publication: 3076

Clinical significance of circulating tumor cells (CTCs) in hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients receiving letrozole or letrozole plus bevacizumab: CALGB 40503 (Alliance)

DOI

URL

Google Scholar

Citation:: J Clin Oncol vol 37 (15_suppl) 1049-1049

Meeting Instance:: ASCO 2019
Year:: 2019
Type:: Abstract
Sub type:: Poster General
Funding:: NCTN
Endpoint:: Secondary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No

Parents:: None
Children:: 3318

Program:: OGC
Primary Committee:: Breast
Sec. Committees:

Pharmas:: Genentech
Grants:: U10CA180821, U10CA180882, U24CA196171

Corr. Author:
Authors:: Mark Jesus M. Magbanua Oleksandr Savenkov Erik J. Asmus Karla V. Ballman Janet H. Scott John W. Park Maura Dickler Ann Partridge Lisa Carey Eric Winer Hope S. Rugo

Networks:: AURORA, CA824, LAPS-CT018, LAPS-MA036, LAPS-NC007, LAPS-NY016

Study: CALGB-40503
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: